Utility of telemedicine in the treatment of patients with chronic HCV infection using DAAs in remote areas with limited resources
- PMID: 34153175
- DOI: 10.1111/liv.14982
Utility of telemedicine in the treatment of patients with chronic HCV infection using DAAs in remote areas with limited resources
Comment on
-
COVID-19 and liver disease.Liver Int. 2020 Jun;40(6):1278-1281. doi: 10.1111/liv.14470. Liver Int. 2020. PMID: 32251539 No abstract available.
References
REFERENCES
-
- Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int. 2020;40:1278-1281. https://doi.org/10.1111/liv.14470.
-
- Ryu S. Telemedicine: opportunities and developments in member states: report on the second global survey on eHealth 2009 (global observatory for eHealth series, volume 2). Healthc Inform Res. 2012;18:153. https://doi.org/10.4258/hir.2012.18.2.153.
-
- Mann DM, Chen J, Chunara R, Testa PA, Nov O. COVID-19 transforms health care through telemedicine: evidence from the field. J Am Med Inform Assoc. 2020;27:1132-1135. https://doi.org/10.1093/jamia/ocaa072.
-
- Arora S, Kalishman S, Thornton K, et al. Expanding access to hepatitis C virus treatment - Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology. 2010;52:1124-1133. https://doi.org/10.1002/hep.23802.
-
- Parimbelli E, Bottalico B, Losiouk E, et al. Trusting telemedicine: a discussion on risks, safety, legal implications and liability of involved stakeholders. Int J Med Inf. 2018;112:90-98.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
